These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 18403134

  • 1. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
    Wilens TE, Adler LA, Weiss MD, Michelson D, Ramsey JL, Moore RJ, Renard D, Brady KT, Trzepacz PT, Schuh LM, Ahrbecker LM, Levine LR, Atomoxetine ADHD/SUD Study Group.
    Drug Alcohol Depend; 2008 Jul 01; 96(1-2):145-54. PubMed ID: 18403134
    [Abstract] [Full Text] [Related]

  • 2. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A, LYCY Study Group.
    Eur Neuropsychopharmacol; 2009 Nov 01; 19(11):822-34. PubMed ID: 19716683
    [Abstract] [Full Text] [Related]

  • 3. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder and comorbid social anxiety disorder.
    Adler LA, Liebowitz M, Kronenberger W, Qiao M, Rubin R, Hollandbeck M, Deldar A, Schuh K, Durell T.
    Depress Anxiety; 2009 Nov 01; 26(3):212-21. PubMed ID: 19194995
    [Abstract] [Full Text] [Related]

  • 4. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME, Hazell P, Danckaerts M, Hoare P, Coghill DR, Wehmeier PM, Williams DW, Moore RJ, Levine L, Atomoxetine ADHD/ODD Study Group.
    Pediatrics; 2008 Feb 01; 121(2):e314-20. PubMed ID: 18245404
    [Abstract] [Full Text] [Related]

  • 5. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders.
    Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ.
    Neurology; 2005 Dec 27; 65(12):1941-9. PubMed ID: 16380617
    [Abstract] [Full Text] [Related]

  • 6. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
    Biederman J, Wigal SB, Spencer TJ, McGough JJ, Mays DA.
    Clin Ther; 2006 Feb 27; 28(2):280-93. PubMed ID: 16678649
    [Abstract] [Full Text] [Related]

  • 7. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome.
    Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M.
    J Atten Disord; 2008 Jan 27; 11(4):470-81. PubMed ID: 17934184
    [Abstract] [Full Text] [Related]

  • 8. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, Newcorn JH, Kratochvil CJ, Gao H, Thomason CK, Rogers AK, Feldman PD, Levine LR.
    J Pediatr; 2006 Jul 27; 149(1):112-9. PubMed ID: 16860138
    [Abstract] [Full Text] [Related]

  • 9. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun 27; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 10. Atomoxetine treatment outcomes in adolescents and young adults with attention-deficit/hyperactivity disorder: results from a post hoc, pooled analysis.
    Adler LA, Wilens T, Zhang S, Dittmann RW, D'Souza DN, Schuh L, Durell TM.
    Clin Ther; 2012 Feb 27; 34(2):363-73. PubMed ID: 22285724
    [Abstract] [Full Text] [Related]

  • 11. Comparison of parent and teacher reports of attention-deficit/hyperactivity disorder symptoms from two placebo-controlled studies of atomoxetine in children.
    Biederman J, Gao H, Rogers AK, Spencer TJ.
    Biol Psychiatry; 2006 Nov 15; 60(10):1106-10. PubMed ID: 16806096
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
    Atomoxetine ADHD and Comorbid MDD Study GroupLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285, USA. bangsme@lilly.com, Bangs ME, Emslie GJ, Spencer TJ, Ramsey JL, Carlson C, Bartky EJ, Busner J, Duesenberg DA, Harshawat P, Kaplan SL, Quintana H, Allen AJ, Sumner CR.
    J Child Adolesc Psychopharmacol; 2007 Aug 15; 17(4):407-20. PubMed ID: 17822337
    [Abstract] [Full Text] [Related]

  • 13. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD.
    Sutherland SM, Adler LA, Chen C, Smith MD, Feltner DE.
    J Clin Psychiatry; 2012 Apr 15; 73(4):445-50. PubMed ID: 22313788
    [Abstract] [Full Text] [Related]

  • 14. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.
    Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D.
    J Atten Disord; 2008 Nov 15; 12(3):248-53. PubMed ID: 18448861
    [Abstract] [Full Text] [Related]

  • 15. Quality of life assessment in adult patients with attention-deficit/hyperactivity disorder treated with atomoxetine.
    Adler LA, Sutton VK, Moore RJ, Dietrich AP, Reimherr FW, Sangal RB, Saylor KE, Secnik K, Kelsey DK, Allen AJ.
    J Clin Psychopharmacol; 2006 Dec 15; 26(6):648-52. PubMed ID: 17110824
    [Abstract] [Full Text] [Related]

  • 16. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M, van de Loo-Neus G, Minderaa RB, van der Gaag RJ, Escobar R, Schacht A, Pamulapati S, Buitelaar JK, Hoekstra PJ.
    J Am Acad Child Adolesc Psychiatry; 2012 Jul 15; 51(7):733-41. PubMed ID: 22721596
    [Abstract] [Full Text] [Related]

  • 17. Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.
    Newcorn JH, Spencer TJ, Biederman J, Milton DR, Michelson D.
    J Am Acad Child Adolesc Psychiatry; 2005 Mar 15; 44(3):240-8. PubMed ID: 15725968
    [Abstract] [Full Text] [Related]

  • 18. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, Rubin RL, Pigott TA, Sarkis EH, Fox BK.
    J Clin Psychopharmacol; 2013 Feb 15; 33(1):45-54. PubMed ID: 23277268
    [Abstract] [Full Text] [Related]

  • 19. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial.
    Wang Y, Zheng Y, Du Y, Song DH, Shin YJ, Cho SC, Kim BN, Ahn DH, Marquez-Caraveo ME, Gao H, Williams DW, Levine LR.
    Aust N Z J Psychiatry; 2007 Mar 15; 41(3):222-30. PubMed ID: 17464703
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year.
    Buitelaar JK, Michelson D, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J.
    Biol Psychiatry; 2007 Mar 01; 61(5):694-9. PubMed ID: 16893523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.